Roivant Sciences LTD 8-K filings

Immunovant reports strong results from a Phase 2a trial of batoclimab in Graves' Disease, showing high response rates and a correlation between IgG reduction and clinical outcomes, with a pivotal trial of IMVT-1402 expected by year-end.

Roivant Sciences announced its first quarter 2024 financial results, highlighted by a net income of $57.5 million and progress in key clinical trials.

Dermavant, a subsidiary of Roivant Sciences, has renegotiated its debt obligations, reducing potential cash payments by over $300 million, with approximately $225 million expected over the next three fiscal years.

Roivant Sciences announced its financial results for the fourth quarter and fiscal year ended March 31, 2024, highlighting positive clinical trial data, a significant share repurchase, and a substantial gain from the sale of Telavant.

Roivant Sciences Ltd. announced positive Phase 2 trial results for brepocitinib in non-infectious uveitis and a $1.5 billion share repurchase program, including the repurchase of all shares held by Sumitomo Pharma.

Roivant Sciences reported a significant net income of $5.1 billion for the quarter ending December 31, 2023, driven by the sale of Telavant to Roche, and provided updates on its clinical programs.